The fossilization of randomized clinical trials.
作者信息
Paneth Nigel S, Joyner Michael J, Casadevall Arturo
机构信息
Department of Epidemiology and Biostatistics, and Pediatrics and Human Development, Michigan State University, College of Human Medicine, East Lansing, Michigan, USA.
Department of Anesthesiology and Perioperative Medicine, Mayo Clinic, Rochester, Minnesota, USA.
出版信息
J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI158499.
Abstract
摘要
相似文献
1
The fossilization of randomized clinical trials.随机临床试验的僵化
J Clin Invest. 2022 Feb 15;132(4). doi: 10.1172/JCI158499.
2
The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial.《凯弗维尔-哈里斯修正案》五十周年：疗效评估与随机临床试验
J Clin Hypertens (Greenwich). 2012 Nov;14(11):810-5. doi: 10.1111/jch.12012. Epub 2012 Oct 3.
3
Introducing a history of key trials in The Lancet.介绍《柳叶刀》上关键试验的历史。
Lancet. 2017 Nov 4;390(10107):2025. doi: 10.1016/S0140-6736(17)31452-6.
4
A brief history of the cluster randomised trial design.整群随机试验设计简史。
J R Soc Med. 2015 May;108(5):192-8. doi: 10.1177/0141076815582303.
5
What did randomised clinical trials do to clinical science?随机临床试验对临床科学产生了什么影响？
Theriaca. 2004(35):68-89.
6
Paradigm shifts in heart-failure therapy--a timeline.心力衰竭治疗的范式转变——时间线
N Engl J Med. 2014 Sep 11;371(11):989-91. doi: 10.1056/NEJMp1410241. Epub 2014 Sep 3.
7
The randomized controlled trial: in celebration of TRANSFUSION's 50th.随机对照试验：庆祝《输血》杂志创刊50周年
Transfusion. 2010 Jun;50(6):1173-8. doi: 10.1111/j.1537-2995.2009.02567.x. Epub 2010 Jan 15.
8
A brief history of the randomized controlled trial. From oranges and lemons to the gold standard.随机对照试验简史。从橙子和柠檬到金标准。
Hematol Oncol Clin North Am. 2000 Aug;14(4):745-60, vii. doi: 10.1016/s0889-8588(05)70309-9.
9
The use of observational research to inform clinical practice.运用观察性研究为临床实践提供信息。
J Clin Invest. 2021 Jan 19;131(2). doi: 10.1172/JCI146392.
10
Significant errors.
Lancet. 2010 Oct 23;376(9750):1390-1; author reply 1391. doi: 10.1016/S0140-6736(10)61954-X.
引用本文的文献
1
Exercise and Experiments of Nature.《自然的锻炼与实验》
Compr Physiol. 2023 Jun 26;13(3):4879-4907. doi: 10.1002/cphy.c220027.
2
Treating COVID-19: Targeting the Host Response, Not the Virus.治疗新冠病毒病：针对宿主反应，而非病毒。
Life (Basel). 2023 Mar 6;13(3):712. doi: 10.3390/life13030712.
3
Monoclonal antibody therapies against SARS-CoV-2.针对 SARS-CoV-2 的单克隆抗体疗法。
Lancet Infect Dis. 2022 Nov;22(11):e311-e326. doi: 10.1016/S1473-3099(22)00311-5. Epub 2022 Jul 5.
4
Biologics in severe asthma: the role of real-world evidence from registries.生物制剂在重症哮喘中的应用：来自登记处的真实世界证据的作用。
Eur Respir Rev. 2022 Jun 7;31(164). doi: 10.1183/16000617.0278-2021. Print 2022 Jun 30.
5
Welcomes Clinical Research Papers That Advance Our Understanding of Human-Microbe Interactions.欢迎有助于增进我们对人类与微生物相互作用理解的临床研究论文。
mBio. 2022 Apr 26;13(2):e0052722. doi: 10.1128/mbio.00527-22. Epub 2022 Mar 29.
本文引用的文献
1
Effect of High-Titer Convalescent Plasma on Progression to Severe Respiratory Failure or Death in Hospitalized Patients With COVID-19 Pneumonia: A Randomized Clinical Trial.高滴度恢复期血浆对 COVID-19 肺炎住院患者进展为严重呼吸衰竭或死亡的影响：一项随机临床试验。
JAMA Netw Open. 2021 Nov 1;4(11):e2136246. doi: 10.1001/jamanetworkopen.2021.36246.
2
Early Treatment for Covid-19 with SARS-CoV-2 Neutralizing Antibody Sotrovimab.Sotrovimab 对 SARS-CoV-2 中和抗体用于治疗新型冠状病毒早期感染。
N Engl J Med. 2021 Nov 18;385(21):1941-1950. doi: 10.1056/NEJMoa2107934. Epub 2021 Oct 27.
3
Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19.皮下注射 REGEN-COV 抗体组合以预防 COVID-19。
N Engl J Med. 2021 Sep 23;385(13):1184-1195. doi: 10.1056/NEJMoa2109682. Epub 2021 Aug 4.
4
Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19.巴尼韦单抗/依特司韦单抗在轻中度 COVID-19 中的应用。
N Engl J Med. 2021 Oct 7;385(15):1382-1392. doi: 10.1056/NEJMoa2102685. Epub 2021 Jul 14.
5
The Effect of Convalescent Plasma Therapy on Mortality Among Patients With COVID-19: Systematic Review and Meta-analysis.恢复期血浆疗法对 COVID-19 患者死亡率的影响：系统评价和荟萃分析。
Mayo Clin Proc. 2021 May;96(5):1262-1275. doi: 10.1016/j.mayocp.2021.02.008. Epub 2021 Feb 17.
6
The Principles of Antibody Therapy for Infectious Diseases with Relevance for COVID-19.针对传染病的抗体治疗原则及其与 COVID-19 的相关性。
mBio. 2021 Mar 2;12(2):e03372-20. doi: 10.1128/mBio.03372-20.
7
Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial.巴尼韦单抗单药或联合埃特司韦单抗治疗轻中度 COVID-19 患者对病毒载量的影响：一项随机临床试验。
JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202.
8
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.早期高滴度血浆疗法预防老年人重症 COVID-19。
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
9
REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.REGN-COV2，一种中和抗体鸡尾酒疗法，用于治疗门诊新冠患者。
N Engl J Med. 2021 Jan 21;384(3):238-251. doi: 10.1056/NEJMoa2035002. Epub 2020 Dec 17.
10
SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.SARS-CoV-2 中和抗体 LY-CoV555 治疗门诊新冠患者的疗效。
N Engl J Med. 2021 Jan 21;384(3):229-237. doi: 10.1056/NEJMoa2029849. Epub 2020 Oct 28.
Zotero 插件